Breaking News
Get 50% Off 0
📌 New AI-picked stocks coming soon. 3 picks from last month are already up +30%...
Get early access
Close

Kyowa Kirin Co Ltd (4151)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
2,588.5 +23.0    +0.90%
05:48:38 - Delayed Data. Currency in JPY
Type:  Equity
Market:  Japan
ISIN:  JP3256000005 
  • Volume: 487,800
  • Bid/Ask: 2,588.5 / 2,589.5
  • Day's Range: 2,558.0 - 2,596.0
Kyowa Kirin 2,588.5 +23.0 +0.90%

Kyowa Kirin Co Ltd Company Profile

 
Get an in-depth profile of Kyowa Kirin Co Ltd, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryPharmaceuticals
SectorHealthcare
Employees

5669

Equity Type

ORD

Kyowa Kirin Co., Ltd. engages in the research, development, manufacturing, sells, and import/export of pharmaceuticals products worldwide. It’s pipeline consist of OTL-203, which is in Phase III clinical trial for the treatment of hurler syndrome; KHK4083/AMG 45, which is in Phase III and II clinical trial for the treatment of atopic dermatitis and prurigo nodularis, and asthma; OTL-201, which is in Phase II clinical trial for the treatment of sanfilippo syndrome type A; ziftomenib, which is in Phase II and I clinical trial for the treatment of acute myeloid Leukemia and acute lymphoblastic leukemia; KHK4951, which is in Phase II clinical trial for the treatment of diabetic macular edema and neovascular age-related macular degeneration; KK8123, which is in Phase I clinical trial for the treatment of x-linked hypophosphatemia; KK2845, which is in Phase I clinical trial for the treatment of acute myeloid leukemia; KK4277, which is in Phase I clinical trial for the treatment of systemic and cutaneous lupus erythematosus; and KK2260 and KK2269 that are in Phase I clinical trial for the treatment of solid tumors. It also develops POTELIGEO, a humanized monoclonal antibody for CC chemokine receptor 4; REGPARA for secondary hyperparathyroidism; Romiplate/Nplate, a genetically recombinant protein that produces platelet; Crysvita, a recombinant human monoclonal IgG1 antibody; NESP, an erythropoiesis stimulating agent; GRAN, a human colony-stimulating factor; and LUMICEF, a biological treatment for moderate to severe plaque psoriasis. In addition, it offers G-Lasta; Duvroq; PHOZEVEL; KK8398; KHK4827; and OTL-200. It has an agreement with Amgen Inc. and Kura Oncology. The company was formerly known as Kyowa Hakko Kirin Co., Ltd. and changed its name to Kyowa Kirin Co., Ltd. in June 2019. The company was incorporated in 1949 and is headquartered in Tokyo, Japan. Kyowa Kirin Co., Ltd. is a subsidiary of Kirin Holdings Company, Limited.

Contact Information

Address 1-9-2, Otemachi Chiyoda-ku
Tokyo, 100-0004
Japan
Phone 81 3 5205 7200
Fax 81 3 5205 7182

Top Executives

Name Age Since Title
Tomomi Yatsu 63 2021 Outside Independent Auditor
Hiroshi Komatsu 63 2018 Full-time Audit & Supervisory Board Member
Mayumi Tamura 65 2022 Outside Audit & Supervisory Board Member
Takashi Oyamada 70 2021 Independent Outside Director
Takeyoshi Yamashita 64 2021 Director, Executive VP & Chief Medical Officer
Toru Ishikura 62 2023 Audit & Supervisory Board Member
Yukiko Ito - 2025 Director
Yoko Wachi - 2025 Audit & Supervisory Board Member
Yoshihisa Q. Suzuki 70 2022 Independent Outside Director
Rumiko Nakata 69 2023 Independent Outside Director
Abdul Hafeez Mullick 58 2022 Representative Director, President & COO
Daisuke Fujiwara - 2025 Director
Hiroshi Kanno - 2025 Director
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

4151 Comments

Write your thoughts about Kyowa Kirin Co Ltd
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email